The U.S. Federal Trade Commission said on February 17 that the FTC would file a lawsuit aimed at stopping the merger of Rhode Island’s two largest health care providers, Lifespan Corp. and Care New England Health System.
The U.S. antitrust regulator asked Biogen Inc. to present documents related to the approval and marketing of the company’s Alzheimer’s disease treatment, the drugmaker disclosed in a filing.
AstraZeneca’s $39 billion acquisition of Alexion is being investigated by the UK’s Competition and Markets Authority (CMA) to determine if the deal is anti-competitive.
A federal appeals court threw out an order requiring AbbVie Inc. and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.
The U.S. Federal Trade Commission sought additional information from Bristol-Myers Squibb Co. and Celgene Corp. and is focusing on the companies’ psoriasis treatments as part of the FTC’s review of their planned merger, Bristol-Myers said.
An appeals court upheld a judge’s decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.
The U.S. health regulator warned a California-based manufacturer and retailer against advertising its e-cigarette liquids with nicotine in a way that may cause the products to resemble kid-friendly food like juice boxes and cookies.
President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.
A U.S. judge found that pharmaceutical company AbbVie Inc. used sham litigation to illegally prevent generic versions of the testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.